
- Volume 0 0
VON ESCHENBACH WINS SENATE APPROVAL
Despite 9 months of holdups by Congress, the Senateapproved the nomination of Acting FDA Commissioner Andrewvon Eschenbach, MD, to permanently head the agency. He hasserved as interim head of the FDA since September 2005.
Republican Sens Charles E. Grassley (Iowa) and DavidVitter (La) had placed holds on the nomination. RetiringMajority Leader Bill Frist (R, Tenn), however, forced a proceduralvote that allowed the Senate to vote on the nominationdespite the holds. During President Bush's term, the FDA hasbeen without a permanent commissioner for all but 18months.
The next year could prove challenging for the agency. Withthe Democrats controlling Congress, many have criticized theFDA on its monitoring of the safety of drugs. Furthermore, thelaw that permits the agency to collect fees from companies toaccelerate the new drug approval process expires in 2007. TheDemocrats will most likely use the reauthorization of the legislationas a means to push for changes at the agency.
Articles in this issue
almost 19 years ago
Preventing Rasagiline Drug Interactionsalmost 19 years ago
nacds SPEAKS OUT: Specialty Pharmaceuticals on the Risealmost 19 years ago
Strategies for Coping with Alzheimer's Diseasealmost 19 years ago
Captive at the Counter: When Robbers Take Hostages—Part 1almost 19 years ago
A Third Category? Medicines Go Behind the Counteralmost 19 years ago
Avoiding Common Dispensing Errorsalmost 19 years ago
Pharm School Receives Grant to Help with Part Dalmost 19 years ago
compounding HOTLINEalmost 19 years ago
The Pharmacist's Role in the Management of Alzheimer's Diseasealmost 19 years ago
A Challenging Path to a PharmD DegreeNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.